Atossa Therapeutics, Inc. (NASDAQ:ATOS - Get Free Report) shares passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $1.24 and traded as low as $0.76. Atossa Therapeutics shares last traded at $0.82, with a volume of 572,873 shares.
Analyst Upgrades and Downgrades
A number of equities research analysts have recently commented on the stock. StockNews.com cut shares of Atossa Therapeutics from a "hold" rating to a "sell" rating in a research report on Monday, November 18th. HC Wainwright reiterated a "buy" rating and issued a $7.00 price objective on shares of Atossa Therapeutics in a report on Thursday, January 30th. Finally, Ascendiant Capital Markets boosted their target price on Atossa Therapeutics from $6.50 to $7.00 and gave the stock a "buy" rating in a report on Monday, December 9th.
Get Our Latest Report on ATOS
Atossa Therapeutics Stock Performance
The firm's 50-day moving average price is $0.95 and its two-hundred day moving average price is $1.22. The stock has a market cap of $104.44 million, a price-to-earnings ratio of -3.77 and a beta of 1.24.
Hedge Funds Weigh In On Atossa Therapeutics
Several institutional investors and hedge funds have recently bought and sold shares of the company. Gallagher Capital Advisors LLC purchased a new stake in shares of Atossa Therapeutics during the 4th quarter valued at approximately $25,000. Intech Investment Management LLC acquired a new stake in Atossa Therapeutics during the third quarter worth $29,000. SG Americas Securities LLC raised its position in Atossa Therapeutics by 254.3% in the third quarter. SG Americas Securities LLC now owns 41,849 shares of the company's stock valued at $64,000 after purchasing an additional 30,037 shares during the period. Wells Fargo & Company MN raised its position in Atossa Therapeutics by 30.7% in the fourth quarter. Wells Fargo & Company MN now owns 71,720 shares of the company's stock valued at $68,000 after purchasing an additional 16,853 shares during the period. Finally, XTX Topco Ltd lifted its stake in shares of Atossa Therapeutics by 101.2% in the 3rd quarter. XTX Topco Ltd now owns 49,616 shares of the company's stock valued at $75,000 after purchasing an additional 24,951 shares during the last quarter. 12.74% of the stock is currently owned by institutional investors and hedge funds.
About Atossa Therapeutics
(
Get Free Report)
Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.
Featured Stories
Before you consider Atossa Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Atossa Therapeutics wasn't on the list.
While Atossa Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
